Revance Therapeutics Inc - Company Profile

Powered by

All the sales intelligence you need on Revance Therapeutics Inc in one solution.

$195 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Revance Therapeutics Inc fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Revance Therapeutics Inc.

Back to companies

Revance Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Revance Therapeutics Inc is a biotechnology company. It is focused on the development, manufacturing, and marketing of novel botulinum toxin products. The company is headquartered in Nashville, Tennessee, the US.

 Gain a 360-degree view of Revance Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Revance Therapeutics Inc and make more informed decisions for your business Learn more
Headquarters United States of America
Address 20th Floor, 1222 Demonbreun Street, Nashville, Tennessee, 37203
Website www.revance.com
Telephone 1 510 7423400
Industry Pharmaceuticals and Healthcare
Revenue (2023) $234.0M
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Revance Therapeutics Inc premium industry data and analytics

40+

Clinical Trials

Determine Revance Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Revance Therapeutics Inc’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Revance Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

15+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Pipeline Drugs

Identify which of Revance Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Revance Therapeutics Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline Revance
DaxibotulinumtoxinA-lanm
Teoxane RHA
XYZ
XYZ
XYZ
Understand Revance Therapeutics Inc portfolio and identify potential areas for collaboration Understand Revance Therapeutics Inc portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Ownership Changes In February, the company was acquired by Crown Laboratories, Inc. for US$924 million.
2025 Plans/Strategy In January, the company announced its plans to be acquired by Teoxane.
2025 Contracts/Agreements In January, the company entered into an agreement with Dermata Therapeutics, Inc. to evaluate the topical application of Dermata's Xyngari with Revance's Daxxify.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader
Executives
Name Position Board Since Age
Jeff Bedard Chairman Executive Board 2025 -
Nadeem Moiz Chief Executive Officer Senior Management 2025 -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Revance Therapeutics Inc key executives to enhance your sales strategy Gain insight into Revance Therapeutics Inc key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?